Nodal status—its impact on prognosis in advanced ovarian cancer

Bachmann, Cornelia; Bachmann, Stefan; Fehm, Tanja; Staebler, A; Becker, Sven; Rothmund, Ralf; Gardanis, C.; Grischke, Eva‐Maria; Wallwiener, D.; Solomayer, Erich

doi:10.1007/s00432-011-1094-x

Cited by 12 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study also showed that optimal cytoreduction was an independent prognostic factor for OS in patients with stage III disease. Bachmann et al [13] reported that the influence of LN metastasis on prognosis decreases with the increase in residual tumor volume. The authors also reported that the nodal status seemed to be the next most important prognostic factor for advanced-stage ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture

Suh

Kim

et al. 2013

J Gynecol Oncol

View full text Add to dashboard Cite

ObjectiveTo evaluate the improvement in prognosis prediction with reassignment of International Federation of Gynecology and Obstetrics (FIGO) stages for ovarian carcinoma.MethodsThis was a retrospective study of patients with epithelial ovarian, fallopian tube, and primary peritoneal cancers. Sub-staging criteria used in stage reassignment were defined as follows: surgical spillage (IC1), capsule rupture before surgery or tumor on the surface (IC2), and positive cytology results (IC3); microscopic (IIB1) and macroscopic (IIB2) pelvic spread; microscopic extrapelvic spread (IIIA1) and retroperitoneal lymph node (LN) metastasis without extrapelvic spread (IIIA2); and supraclavicular LN metastasis (IVA) and other distant metastasis (IVB). Survival outcomes associated with the current and reassigned stages were compared.ResultsOverall, 870 patients were eligible for analysis. The median follow-up period was 45 months (range, 0 to 263 months). The 5-year overall survival rates (5YSRs) according to the current staging were 93.5% (IA), 82.5% (IC), 75.0% (IIB), 74.5% (IIC), 57.5% (IIIA), 54.0% (IIIB), 38.5% (IIIC), and 33.0% (IV). The 5YSRs of patients with IC1, IC2, and IC3 after sub-staging were 92.0%, 85.0%, and 71.0%, respectively (p=0.004). Patients who were reassigned to stage IIIA2 had a better 5YSR than those with extrapelvic tumors >2 cm (66.3% vs. 35.8%; p=0.005). Additionally, patients with newly assigned stage IVA disease had a significantly better 5YSR than those with stage IVB disease (52.0% vs. 28.0%; p=0.015).ConclusionThe modified FIGO staging for ovarian carcinoma appears superior to the current staging for discriminating survival outcomes of patients with surgical spillage, retroperitoneal LN metastasis without extrapelvic peritoneal involvement, or distant metastasis to supraclavicular LNs.

show abstract

Section: Discussionmentioning

confidence: 99%

Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture

Suh

Kim

et al. 2013

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…In patients with EOC, prognosis is determined based on analysis of cancer-related risk factors. A wide variety of features of high-risk cancer, including size of the tumor, size of the residual tumor 2 , stage of the cancer 5 , lymph node status 6 , histologic type 7 , histologic grade 8 , malignant ascites 9 , and cancer antigen 125 (CA-125) levels 10 are considered essential for predicting cancer-specific survival.…”

Section: Introductionmentioning

confidence: 99%

The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer

Chang

Kwon

et al. 2016

J. Cancer

View full text Add to dashboard Cite

Objective: To measure the prognostic value of the lymphocyte-monocyte ratio (LMR) in patients with epithelial ovarian cancer (EOC).Methods: We retrospectively examined the LMR as a prognosticator in a cohort of 234 patients with EOC who underwent surgical resection. Patients were categorized into two different groups based on the LMR (LMR-low and LMR-high) using cut-off values determined by receiver operating characteristic (ROC) curve analysis. The objective of the study was to assess the effect of the LMR on progression-free survival (PFS) and overall survival (OS), and to validate the LMR as an independent predictor of survival.Results: Using the data collected from the whole cohort, the optimized LMR cut-off value selected on the ROC curve was 2.07 for both PFS and OS. The LMR-low and LMR-high groups included 48 (20.5%) and 186 patients (79.5%), respectively. The 5-year PFS rates in the LMR-low and LMR-high groups were 40.0 and 62.5% (P < 0.0001), respectively, and the 5-year OS rates in these two groups were 42.2 and 67.2% (P < 0.0001), respectively. On multivariate analysis, we identified age, International Federation of Gynecology and Obstetrics (FIGO) stage, and cancer antigen 125 levels to be the strongest valuable prognostic factors affecting PFS (P = 0.0421, P = 0.0012, and P = 0.0313, respectively) and age, FIGO stage, and the LMR as the most valuable prognostic factors predicting OS (P = 0.0064, P = 0.0029, and P = 0.0293, respectively).Conclusion: The LMR is an independent prognostic factor affecting the survival of patients with EOC.

show abstract

“…The prognostic relevance of lymph node metastases in primary ovarian cancer is unclear, although seen as an important prognostic factor for advanced-stage ovarian cancer, there is contradictory data on survival after systematic lymphadenectomy versus bulky node resection [19][20][21][22] .…”

Section: Discussionmentioning

confidence: 99%

Clinico‑morphological aspects and new immunohistochemistry characteristics of ovarian high‑grade serous carcinoma

Popa¹,

COROBEA²,

Cîrstoiu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

Nodal status—its impact on prognosis in advanced ovarian cancer

Cited by 12 publications

References 28 publications

Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture

Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture

The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer

Clinico‑morphological aspects and new immunohistochemistry characteristics of ovarian high‑grade serous carcinoma

Contact Info

Product

Resources

About